Collegium Pharmaceutical (NASDAQ:COLL) Price Target Cut to $56.00 by Analysts at Barclays

Collegium Pharmaceutical (NASDAQ:COLL) had its price objective decreased by research analysts at Barclays from $58.00 to $56.00 in a research note issued on Friday,Benzinga reports. The firm presently has an “overweight” rating on the specialty pharmaceutical company’s stock. Barclays‘s price target points to a potential upside of 22.05% from the stock’s previous close.

A number of other analysts have also weighed in on COLL. Weiss Ratings reissued a “buy (b-)” rating on shares of Collegium Pharmaceutical in a report on Monday, December 29th. Zacks Research lowered Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. HC Wainwright reissued a “buy” rating and issued a $60.00 target price (up from $46.00) on shares of Collegium Pharmaceutical in a research note on Friday. Needham & Company LLC boosted their target price on Collegium Pharmaceutical from $48.00 to $56.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Wall Street Zen upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Five research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $52.80.

Collegium Pharmaceutical Price Performance

Shares of Collegium Pharmaceutical stock traded down $2.90 during trading on Friday, reaching $45.88. The company’s stock had a trading volume of 66,260 shares, compared to its average volume of 474,577. The stock has a 50-day moving average price of $46.04 and a two-hundred day moving average price of $38.38. The stock has a market capitalization of $1.45 billion, a P/E ratio of 28.85 and a beta of 0.60. The company has a current ratio of 1.36, a quick ratio of 1.27 and a debt-to-equity ratio of 2.71. Collegium Pharmaceutical has a one year low of $23.23 and a one year high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 earnings per share for the quarter. Collegium Pharmaceutical had a net margin of 7.72% and a return on equity of 102.03%. The firm had revenue of $135.55 million during the quarter. As a group, sell-side analysts anticipate that Collegium Pharmaceutical will post 5.62 EPS for the current fiscal year.

Insider Buying and Selling

In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 17,600 shares of the business’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $48.17, for a total transaction of $847,792.00. Following the sale, the executive vice president directly owned 103,613 shares of the company’s stock, valued at $4,991,038.21. The trade was a 14.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Colleen Tupper sold 30,000 shares of the stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $40.53, for a total value of $1,215,900.00. Following the transaction, the chief financial officer directly owned 126,667 shares of the company’s stock, valued at $5,133,813.51. This trade represents a 19.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 51,250 shares of company stock valued at $2,235,352. 2.51% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its position in shares of Collegium Pharmaceutical by 9.6% during the 4th quarter. GAMMA Investing LLC now owns 3,262 shares of the specialty pharmaceutical company’s stock valued at $151,000 after acquiring an additional 285 shares during the period. JPMorgan Chase & Co. increased its position in shares of Collegium Pharmaceutical by 193.8% in the third quarter. JPMorgan Chase & Co. now owns 211,757 shares of the specialty pharmaceutical company’s stock worth $7,409,000 after purchasing an additional 139,689 shares during the period. Tudor Investment Corp ET AL acquired a new position in Collegium Pharmaceutical in the third quarter valued at about $560,000. NewEdge Advisors LLC lifted its position in Collegium Pharmaceutical by 535.9% during the third quarter. NewEdge Advisors LLC now owns 19,376 shares of the specialty pharmaceutical company’s stock worth $678,000 after purchasing an additional 16,329 shares during the period. Finally, Caxton Associates LLP acquired a new stake in Collegium Pharmaceutical during the third quarter worth about $961,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.